Skip to content

Application of an intelligent mobile isolation operating cabin preventing COVID-19 infection

Application of an intelligent mobile isolation operating cabin preventing COVID-19 infection

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039640
Enrollment
Unknown
Registered
2020-11-04
Start date
2020-11-30
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Interventions

Case series:Perform coronary angiography in intelligent mobile isolation operating cabin

Sponsors

Beijing Tsinghua Changgung Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Healthy people between 18 and 60 years old; 2. The subjects whose physical examination or experimental examination meet the needs of the experiment; 3. The subject of mental maturity, with literacy and normal communication skills; 4. The subjects who are willing to participate in the experiment.

Exclusion criteria

Exclusion criteria: 1. Patients with aphasia, severe cognitive impairment and moderate depression (BDI-II score >= 20); 2. Patients with unstable condition, including postural hypotension, sepsis, epilepsy, etc; 3. Patients with unilateral neglect or severe visual impairment; 4. In patients with upper limb spasm, the degree of Ashworth spasm in the shoulder, elbow or wrist hand of the affected limb was greater than grade 2; 5. Patients with heart, lung, liver, kidney and other important organ dysfunction or failure; 6. Patients with pacemaker, intracranial metal implant or skull defect; 7. Patients with severe cervical lesions, including severe cervical spinal stenosis and cervical instability. In the course of the experiment, the following situations will terminate the clinical trial, and the patients will have new neurological diseases or severe pain, spasm and other adverse effects. 8. Patients diagnosed with diabetes and receiving treatment; 9. Patients with mental illness, emotional problems, history of alcohol or other substance abuse; 10. Patients with gastrointestinal diseases and special diet adjustment; 11. Patients with other serious diseases; 12. Patients who used psychotropic drugs, sleeping pills, stimulants or painkillers in the past month or at present; 13. Subjects with irregular sleep caused by shift work or other reasons; 14. Habitual smokers (more than 6 cigarettes per week) or drinkers (more than 7 drinks per week or alcoholic beverages); 15. Patients undergoing phototherapy; 16. The objects who use drugs that affect sleep or appetite; 17. Subjects allergic to heparin; 18. Subjects of pregnancy and lactation; 19. Patients with congenital or other neurological disorders; 20. Subjects who have participated in other clinical trials in the past three months; 21. Patients with recent upper respiratory tract infection. 22. Claustrophobic patients.

Design outcomes

Primary

MeasureTime frame
image quality;

Countries

China

Contacts

Public ContactPing Zhang

Beijing Tsinghua Changgung Hospital

zhpdoc@126.com+86 13910036632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026